1-8 of 8
Christophe Queva, PhD
Close
Sort by
Journal Articles

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Rick Sorensen, BS, Sarah Meadows, Anella Yahiaoui, BS, Li Li, PhD, Peng Yue, PhD, Adam Kashishian, BS, Christophe Queva, PhD, Stacey Tannheimer, PhD
Journal: Blood
Blood (2015) 126 (23): 2482.
https://doi.org/10.1182/blood.V126.23.2482.2482
Published: 2015
Journal Articles

An Innovative High-Throughput Ex Vivo Drug Assay Incorporating the Native Microenvironment Reveals a Novel Mechanism of Action of Idelalisib in CLL

Joan Ballesteros, Lydia Scarfo, Mattias Mattsson, Aliki Xochelli, Pamela Ranghetti, Daniel Primo, Alicia Robles, Julian Gorrochategui, Joaquin Martinez-Lopez, Javier De la Serna, Marcos González, MD PhD, Veerendra Munugalavadla, Richard Rosenquist, Kostas Stamatopoulos, Christophe Quéva, PhD, Paolo Ghia, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2485.
https://doi.org/10.1182/blood.V126.23.2485.2485
Published: 2015
Journal Articles

Up-Regulation of the PI3K Signaling Pathway Mediates Resistance to Idelalisib

Sarah Meadows, Sorensen Rick, Yahiaoui Anella, Jia Liu, PhD, Li Li, PhD, Peng Yue, PhD, Christophe Queva, PhD, Stacey Tannheimer, PhD
Journal: Blood
Blood (2015) 126 (23): 3707.
https://doi.org/10.1182/blood.V126.23.3707.3707
Published: 2015
Journal Articles

Combination of Idelalisib and ONO/GS-4059 in Lymphoma Cell Lines Sensitive and Resistant to BTK Inhibitors

Stacey Tannheimer, PhD, Jia Liu, PhD, Rick Sorensen, BS, Anella Yahiaoui, BS, Sarah Meadows, Li Li, PhD, Peng Yue, PhD, Kathleen S Keegan, PhD, Jamie Bates, PhD, Daniel Tumas, PhD DVM, Christophe Queva, PhD
Journal: Blood
Blood (2015) 126 (23): 3697.
https://doi.org/10.1182/blood.V126.23.3697.3697
Published: 2015
Journal Articles

Combination Effects of B Cell Receptor Pathway Inhibitors (Entospletinib, ONO/GS-4059, and Idelalisib) and a BCL-2 Inhibitor in Primary CLL Cells

Randall Jones, B.A., Mark Joseph Axelrod, PhD, Daniel Tumas, PhD DVM, Christophe Quéva, PhD, Julie Di Paolo, PhD
Journal: Blood
Blood (2015) 126 (23): 1749.
https://doi.org/10.1182/blood.V126.23.1749.1749
Published: 2015
Journal Articles

The PI3K Delta Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function and B Cell Depletion Mediated By Obinutuzumab (GA101) and Rituximab

Sylvia Herter, PhD, Adam Palazzo, Marina Bacac, PhD, Laura Grosmaire, MS, Christian Frey, PhD, Stefan Pflanz, PhD, Jia Liu, PhD, Stacey Tannheimer, PhD, Pablo Umana, PhD, Christian Klein, PhD, Christophe Queva, PhD
Journal: Blood
Blood (2014) 124 (21): 3342.
https://doi.org/10.1182/blood.V124.21.3342.3342
Published: 2014
Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS
Journal: Blood
Blood (2013) 122 (21): 4065.
https://doi.org/10.1182/blood.V122.21.4065.4065
Published: 2013
Journal Articles

Development of a New Fully Human Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies.

Gadi Gazit Bornstein, PhD, Christophe Queva, PhD, Mohammad Tabrizi, PhD, Anne VanAbbema, Carlos Chavez, Ping Wang, Naomi Laing, PhD, Sandhya Raja, PhD, Shenghua Wen, MD, Xianhui Rong, Larry L. Green, PhD, Xiaodong Yang, PhD, David Blakey, PhD
Journal: Blood
Blood (2007) 110 (11): 2349.
https://doi.org/10.1182/blood.V110.11.2349.2349
Published: 2007